Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Still, while Ozempic and Wegovy have secured status ... “The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

May 16 (Reuters) - Ozempic-maker Novo Nordisk (NOVOb.CO ... On May 16, Novo Nordisk says Jorgensen will step down, citing recent market challenges and a slide in the stock since mid-2024.

will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded versions of Ozempic and Wegovy, along with Eli ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...